Development and external validation of nomograms in oropharyngeal cancer patients with known HPV-DNA status:a European Multicentre Study (OroGrams) by Grønhøj, Christian et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Development and external validation of nomograms in oropharyngeal cancer patients
with known HPV-DNA status
Grønhøj, Christian; Jensen, David H; Dehlendorff, Christian; Marklund, Linda; Wagner,
Steffen; Mehanna, Hisham; Munck-Wikland, Eva; Ramqvist, Torbjörn; Näsman, Anders;
Wittekindt, Claus; Würdemann, Nora; Sharma, Shachi Jenny; Gattenlöhner, Stefan; Kiss,
Katalin; Andersen, Elo; Spruce, Rachel; Batis, Nikos; Robinson, Max; Harrington, Kevin;
Winter, Stuart; Jones, Terence M; Klussmann, Jens Peter; Dalianis, Tina; Friborg, Jeppe; von
Buchwald, Christian
Published in:
British Journal of Cancer
DOI:
10.1038/s41416-018-0107-9
Publication date:
2018
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY
Citation for published version (APA):
Grønhøj, C., Jensen, D. H., Dehlendorff, C., Marklund, L., Wagner, S., Mehanna, H., ... von Buchwald, C.
(2018). Development and external validation of nomograms in oropharyngeal cancer patients with known HPV-
DNA status: a European Multicentre Study (OroGrams). British Journal of Cancer, 118(12), 1672-1681.
https://doi.org/10.1038/s41416-018-0107-9
Download date: 03. Feb. 2020
ARTICLE
Epidemiology
Development and external validation of nomograms in
oropharyngeal cancer patients with known HPV-DNA status:
a European Multicentre Study (OroGrams)
Christian Grønhøj1, David H. Jensen1, Christian Dehlendorff2, Linda Marklund3, Steffen Wagner4, Hisham Mehanna5,
Eva Munck-Wikland3, Torbjörn Ramqvist3, Anders Näsman6, Claus Wittekindt4, Nora Würdemann4, Shachi Jenny Sharma4,
Stefan Gattenlöhner7, Katalin Kiss8, Elo Andersen9, Rachel Spruce5, Nikos Batis5, Max Robinson10, Kevin Harrington11, Stuart Winter12,
Terence M. Jones13, Jens Peter Klussmann4, Tina Dalianis6, Jeppe Friborg14 and Christian von Buchwald1
BACKGROUND: The proxy marker for human papillomavirus (HPV), p16, is included in the new AJCC 8th/UICC 8th staging system,
but due to incongruence between p16 status and HPV infection, single biomarker evaluation could lead to misallocation of patients.
We established nomograms for overall survival (OS) and progression-free survival (PFS) in patients with oropharyngeal squamous
cell carcinoma (OPSCC) and known HPV-DNA and p16 status, and validated the models in cohorts from high- and low-prevalent
HPV countries.
METHODS: Consecutive OPSCC patients treated in Denmark, 2000–2014 formed the development cohort. The validation cohorts
were from Sweden, Germany, and the United Kingdom. We developed nomograms by applying a backward-selection procedure for
selection of variables, and assessed model performance.
RESULTS: In the development cohort, 1313 patients, and in the validation cohorts, 344 German, 503 Swedish and 463 British
patients were included. For the OS nomogram, age, gender, combined HPV-DNA and p16 status, smoking, T-, N-, and M-status and
UICC-8 staging were selected, and for the PFS nomogram the same variables except UICC-8 staging. The nomograms performed
well in discrimination and calibration.
CONCLUSIONS: Our nomograms are reliable prognostic methods in patients with OPSCC. Combining HPV DNA and p16 is essential
for correct prognostication. The nomograms are available at www.orograms.org.
British Journal of Cancer (2018) 118:1672–1681; https://doi.org/10.1038/s41416-018-0107-9
INTRODUCTION
In most parts of the Western world, the main risk factor for
oropharyngeal squamous cell carcinoma (OPSCC) is now infection
with high-risk human papillomavirus (HPV); while, a smaller
proportion is related to a high consumption of alcohol and
smoking tobacco.1–4 Patients with HPV-associated OPSCCs have
improved survival probably related to a different mutational
proﬁle,5,6 immune response7–9 and clinical features.10
p16 overexpression is a proxy marker for HPV-driven carcino-
genesis which is the main prognostic factor in patients with
OPSCC. Consequently, p16 was included in the newly proposed
American Joint Committee on Cancer/Union for International
Cancer Control (AJCC-8/UICC-8) staging system. However, an
estimated 10–20% of all OPSCCs are p16-positive, but HPV-
negative, due to alternative cellular events leading to p16
overexpression11,12 being most apparent in oropharyngeal non-
tonsillar, non-base of tongue cancer.13 Hence, it may be
suboptimal to stratify patients based on evaluation of a single
biomarker (i.e. p16 alone) due to the risk of misclassiﬁcation of
tumours and thereby misallocation of patients with an undesired
prognosis.14,15 The combination of HPV-DNA and p16 status has
shown better prognostication.16 Available nomograms so far for
patients with OPSCC do not include combined HPV-DNA and
p16 status, and models have not been externally validated across
areas with high and low HPV prevalence.17,18
A nomogram is a graphical illustration of a statistical model for
calculating the cumulative effect of several variables on a
particular outcome, and nomograms have been developed to
www.nature.com/bjc
Received: 17 November 2017 Revised: 2 March 2018 Accepted: 12 April 2018
Published online: 24 May 2018
1Department of Otorhinolaryngology, Head and Neck Surgery and Audiology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; 2Statistics and
Pharmacoepidemiology, Danish Cancer Society Research Center, Copenhagen, Denmark; 3Department of Clinical Science and Technology (CLINTEC), Karolinska Institutet,
Stockholm, Sweden; 4Department of Otorhinolaryngology, Head and Neck Surgery, University of Giessen, Giessen, Germany; 5Head and Neck Studies and Education (InHANSE),
University of Birmingham, Birmingham, UK; 6Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; 7Department of Pathology, University of Giessen,
Giessen, Germany; 8Department of Pathology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; 9Department of Oncology, Herlev Hospital, University of
Copenhagen, Copenhagen, Denmark; 10Centre for Oral Health Research, Newcastle University, Newcastle, UK; 11The Institute of Cancer Research/The Royal Marsden NIHR
Biomedical Research Centre, London, UK; 12Department of Otorhinolaryngology, Head and Neck Surgery, Nufﬁeld Department of Medicine, Oxford, UK; 13Institute of Translational
Medicine, University of Liverpool, Liverpool, UK and 14Department of Oncology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Correspondence: Christian Buchwald (christian.buchwald@regionh.dk)
© Cancer Research UK 2018
predict clinical endpoints for patients with several types of
malignancies. In this study, we aimed to identify OPSCC- and
patient-related factors associated with OS and PFS, and to
construct and externally validate predictive nomograms. More-
over, this is the ﬁrst study addressing patients treated for an
OPSCC encompassing high and low HPV-prevalent countries in
validation cohorts, and incorporating the newly published AJCC-8/
UICC-8 staging system reﬁning prognostication by employing
both HPV-DNA and p16 status.
MATERIALS AND METHODS
Patient cohorts and determination of p16 overexpression and
presence of HPV DNA
The development cohort. Consecutive patients diagnosed with
OPSCC and treated with curative intent in eastern Denmark
between 2000 and 2014 were included in the development
cohort.1,19,20 Using the unique resident code from the Danish Civil
Registration System, we linked the Danish Head and Neck Cancer
Group (DAHANCA)21 database and the Danish Pathology Data
Registry (DPDR),22 to identify patients. Patient characteristics were
retrieved from these databases as well as from medical records.
Curative radiotherapy regimens consisted of 66–68 Gy, divided
into 33–34 fractions given 6 days a week. From 2007, stage III–IV
(UICC 7th) patients were offered concurrent chemotherapy
(primarily weekly cisplatin 40mg/sqm), if tolerated, whilst a
minority were treated with cetuximab.
An expert head-and-neck pathologist re-validated a
haematoxylin–eosin (H&E)-stained section of each tumour.
p16 staining was considered positive if there was a strong and
diffuse nuclear and cytoplasmic reaction in more than 70% of the
tumour cells.23 Immunohistochemistry for p16 was performed
using the Ventana Benchmark Ultra autostainer with the UltraView
detection kit and the p16 monoclonal antibody E6H4 ready-to-use
with CC1 as a pretreatment (Roche, Tuscon, USA).
DNA was isolated from two to four 10-μm sections using the
DSP DNA Mini Kit and the QIAsymphony SP kit (Qiagen, Hilden,
Germany), according to the manufacturers’ instructions. HPV DNA
PCR was performed using the general primers GP5+/6+ and
Platinum Taq DNA polymerase (Invitrogen, Naerum, Denmark). All
GP5+/6+ PCR negative samples were subject to a GAPDH
(housekeeping gene) PCR to conﬁrm DNA quality. HPV DNA
amplicons were run on the QIAxcel Advanced System using the
QX DNA Screening Gel (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. The expected amplicon sizes were
~150 base pairs (bp) for GP5+/6+ and 200 bp for GAPDH.
Negative samples were resolved on a 2.5% agarose gel stained
with ethidium bromide to compare the sensitivity of the current
assay with the standard. Approximately 50% of all samples were
analysed by HPV PCR and the HPV+ cases were subsequently
sequenced for HPV typing.1 The remaining samples were analysed
by HPV PCR.19,20 The GP5+/GP6+ primers used24 are known to
amplify at least 37 mucosal HPV types,25 namely 14 high-risk HPV
types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68, and 23
low-risk HPV types 6, 11, 26, 34, 40, 42, 43, 44, 53, 54, 55, 57, 61, 70,
71, 72, 73, 81, 82/MM4, 82/IS39, 83, 84 and 89. The speciﬁc HPV
types can then be identiﬁed by, e.g. sequencing of the resulting
amplicons.1
The validation cohorts. Three independent cohorts formed the
external validation cohorts. The populations consisted of patients
with OPSCC treated with curative intent at Karolinska University
Hospital (Stockholm, Sweden; 2005–2012), Giessen University
Hospital (Giessen, Germany; 2000–2009) and The Predictr
Consortium, United Kingdom (UK) (2001–2012).
The Swedish cohort was classiﬁed using p16 immunohisto-
chemistry (clone JC8, dilution 1:100, Santa Cruz Biotechnology, CA,
USA or clone E6H4, DakoCytomation A/S, Carpinteria, CA, USA)
Table 1. Patient characteristics in the four cohorts
Variable Eastern
Denmark
Giessen,
Germany
Karolinska,
Sweden
The Predictr
Consortium,
UK
Number of
patients
1313 344 503 463
Overall survival
(median [IQR])
3.62 [1.85,
5.00]
3.97 [1.18,
5.00]
5.00 [3.33,
5.00]
3.77 [1.73,
5.00]
Overall survival (%)
Censored 888 (63.8) 164 (45.7) 389 (71.9) 420 (62.6)
Events 503 195 (54.3) 151 (27.9) 177 (26.4)
NA 0 (0.0) 0 (0.0) 1 (0.2) 74 (11.0)
Progression-
free survial
(median [IQR])
2.74 [1.12,
5.00]
2.48 [0.77,
5.00]
5.00 [2.46,
5.00]
3.59 [1.43,
5.00]
Progression-free survival (%)
Censored 794 (57.1) 139 (38.7) 364 (67.3) 397 (59.2)
Events 545 (39.2) 220 (61.3) 174 (32.2) 203 (30.3)
NA 52 (3.7) 0 (0.0) 3 (0.6) 71 (10.6)
Smoking (%)
Current 509 (38.8) 265 (77.0) 178 (35.4) 183 (39.5)
Former 532 (40.5) 40 (11.6) 164 (32.6) 156 (33.7)
Never 272 (20.7) 39 (11.3) 161 (32.0) 124 (26.8)
Male (%) 947 (72.1) 265 (77.0) 373 (74.2) 340 (73.4)
Age at
diagnosis
(median [IQR])
59.81
[53.93,
66.38]
58.89
[52.69,
64.97]
60.00 [53.00,
67.00]
56.00 [50.00,
63.00]
HPV-DNA and p16 status (%)
HPV–/p16– 411 (31.3) 233 (67.7) 85 (16.9) 141 (30.5)
HPV–/p16+ 84 (6.4) 23 (6.7) 27 (5.4) 31 (6.7)
HPV+/p16– 59 (4.5) 21 (6.1) 36 (7.2) 18 (3.9)
HPV+/p16+ 759 (57.8) 67 (19.5) 355 (70.6) 273 (59.0)
T (%)
T1 278 (21.2) 75 (21.8) 124 (24.7) 85 (18.4)
T2 614 (46.8) 98 (28.5) 178 (35.4) 184 (39.7)
T3 296 (22.5) 84 (24.4) 101 (20.1) 100 (21.6)
T4 125 (9.5) 87 (25.3) 100 (19.9) 94 (20.3)
N (%)
N0 282 (21.5) 95 (27.6) 101 (20.1) 116 (25.1)
N1 686 (52.2) 47 (13.7) 94 (18.7) 77 (16.6)
N2 206 (15.7) 187 (54.4) 287 (57.1) 252 (54.4)
N3 139 (10.6) 15 (4.4) 21 (4.2) 18 (3.9)
M1 (%) 15 (1.1) 31 (9.0) 4 (0.8) 3 (0.6)
Treatment (%)
RT 698 (53.2) 19 (5.5) 292 (58.1) 47 (10.2)
RT+ C 585 (44.6) 121 (35.2) 201 (40.0) 154 (33.3)
Surgery+
RT/C
10 (0.8) 138 (40.1) 0 (0.0) 229 (49.5)
Surgery 20 (1.5) 52 (15.1) 0 (0.0) 33 (7.1)
Unspeciﬁed
curative
treatment
0 (0.0) 14 (4.1) 10 (2.0) 0 (0.0)
UICC8 (%)
I 587 (44.7) 58 (16.9) 97 (19.3) 66 (14.3)
II 260 (19.8) 63 (18.3) 222 (44.1) 224 (48.4)
III 206 (15.7) 50 (14.5) 105 (20.9) 87 (18.8)
IV 260 (19.8) 173 (50.3) 79 (15.7) 86 (18.6)
RT radiation therapy, C chemotherapy
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and high-risk HPV-DNA detection by a bead-based multiplex assay
on a Magpix instrument (LUMINEX Inc., Austin, TX, USA).9 The
Magpix instrument is known to amplify the 27 HPV types: HPV 6,
11, 16, 18, 26, 30, 31, 33, 35, 39, 42, 43, 44, 45, 51, 52, 53, 56, 58, 59,
66, 67, 68, 69, 70, 73 and 82.
The German cohort was classiﬁed using p16 immunohisto-
chemistry (CINtec histology, Roche mtm laboratories) and high-
risk HPV-DNA detection by PCR followed by bead-based
hybridisation (Luminex Technology, Multimetrix, Progen, Heidel-
berg, Germany).26 This assay detects the following 24 HPV types:
16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82, three
putative high-risk types (26, 53 and 66) and six low-risk types (6,
11, 42, 43, 44 and 70).
The UK cohort was classiﬁed using p16 immunohistochemistry
(CINtec histology, Roche mtm laboratories) and high-risk HPV DNA
in situ hybridisation (Inform HPV III, Ventana Medical Systems
Inc.).3 INFORM HPV III Family 16 probe B detects HPV-16, -18, -31,
-33, -35, -39, -45, -51, -52, -56, -58 and 66.
Overexpression of p16 (>70% positive staining) was classiﬁed
similar to the Danish cohort for all three validation cohorts.
Treatment modalities for the validation cohorts are presented in
more detail in Table 1.
Statistics
Covariates available for adjustment are described in Table 1. Age
was included as a continuous variable in the analyses, and the
remaining variables were included as categorical variables. Overall
survival (OS) was deﬁned as the time from diagnosis of OPSCC to
death from any cause. Progression was based on a biopsy or
relevant imaging and progression-free survival (PFS) was deﬁned
as the time from diagnosis of OPSCC to time of progression at any
site or death from any cause. Patients were censored at the last
date of follow-up, or administratively censored 5 years after
diagnosis. Kaplan–Meier curves were used to illustrate survival
differences and signiﬁcant differences were assessed with log-rank
tests.
To evaluate which covariates inﬂuenced survival, we ﬁtted
multivariate Cox regression analyses with all factors in Table 1
except treatment included (full model), and ties were handled
with the method suggested by Efron. Subsequently, we simpliﬁed
the full models using a stepwise backward-elimination procedure
1.00
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Fig. 1 Kaplan–Meier curves depicting overall survival probability for HPV+/p16+ patients vs. HPV–/p16– patients
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with Akaike’s information criteria as stopping criteria (ﬁnal model)
using the R package rms and the function fastbw.27 All models are
multivariable, i.e. factors are mutually adjusted, and thus the effect
estimates cannot be interpreted marginally. In a subanalysis, we
evaluated the effect of ﬁtting a spline for age in the development
model. This sub-analysis was for the nonlinear part of the spline
considered as non-signiﬁcant; e.g. OS (p= 0.92) and PFS (p =
0.85).
To test whether the assumption of proportional hazards was
violated, we tested for trends in the scaled Schoenfeld residuals of
the ﬁnal models.28 None of the ﬁnal models violated the
proportional hazards assumption. Based on the ﬁnal models,
nomograms were constructed to predict overall survival and PFS
at 1, 3 and 5 years after diagnosis. We considered only complete
cases (e.g. patients were excluded from the analysis in the case of
missing information from one or more variables). p values less
than 5% were considered signiﬁcant and all analyses were
performed in R version 3.0.3.29
Validation and calibration of multivariate Cox regression models
We conducted external validation by applying our nomograms to
the patient cohorts from Sweden, United Kingdom and Germany.
We assessed nomogram model performance by examining overall
accuracy (Brier score),30 calibration plots31 and discrimination
(Harrell’s C index).32 In addition, we ﬁtted a Weibull calibration
model, as suggested by van Houwelingen and Putter, in which
shifts in baseline cumulative hazard (obtained from the ﬁnal Cox
models), the effect of the prognostic index (the linear predictor in
the Cox model) and the shape of the cumulative baseline hazard
were tested.33 A smoothed version of the cumulative baseline
hazard was used in the calibration model, where smoothing was
done by linear interpolation.
RESULTS
Population demographics
The development cohort consisted of 1313 patients with a total of
457 deaths (35%) during follow-up (Table 1). The majority of
patients were males (72%), with a median age of 59.8 years at
diagnosis, and had most frequently HPV+/p16+ tumours (58%).
Patients typically presented with tumours in advanced nodal stage
(78% with N+), with small primary tumours (68% T1 or T2), and in
early UICC8 stage (65% UICC8 stage I or II). OS was for the HPV
+/p16+ patients 95% (95% CI 93–96%) after 1 year, 86% (95% CI
84–89%) after 3 years and 80% (95% CI 77–83%) after 5 years of
follow-up, and for the HPV–/p16– patients 71% (95% CI 65–74%)
after 1 year, 46% (95% CI 41–51%) after 3 years and 34% (95% CI
29–39%) after 5 years (Fig. 1, Table 2). Demographic information
and treatment modality for the validation cohorts are shown in
Table 1.
Overall survival
Five-year OS for the HPV+/p16+ patients in the Swedish cohort
was 81% (95% CI 77–85%) and for the HPV–/p16– patients 40%
(95% CI 31–52%); for the German cohort 81% (95% CI 72–91%)
and 35% (95% CI 30–42%) and in the UK cohort it was 82% (95%
CI 77–87%) and 42% (95% CI 34–52%) (Fig. 1, Table 2, Suppl.
Table S1).
The backwards elimination procedure left the model for overall
survival unchanged, i.e. the model included age, gender,
combined HPV and p16 status, smoking, T-, N-, and M-
classiﬁcation and UICC-8 staging (Table 3). The OS nomogram
Table 2. Overall survival estimates HPV+/p16+ and HPV–/p16– patients
Eastern Denmark Karolinska, Sweden Giessen, Germany The Predictr Consortium, UK
OS HPV+/p16+ HPV+/p16+ HPV+/p16+ HPV+/p16+
1-year 95% (93–96%) 96% (94–98%) 91% (84–98%) 97% (95–99%)
3-year 86% (84–89%) 88% (85–91%) 84% (75–93%) 87% (83–91%)
5-year 80% (77–83%) 81% (77–85%) 81% (72–91%) 82% (77–87%)
OS HPV–/p16– HPV–/p16– HPV–/p16– HPV–/p16–
1-year 71% (67–75%) 69% (60–80%) 76% (71–82%) 74% (67–82%)
3-year 46% (41–51%) 48% (39–60%) 47% (41–54%) 52% (44–62%)
5-year 34% (29–39%) 38% (29–49%) 35% (30–42%) 42% (34–52%)
Censored cases n= 888 (63.8%) n= 389 (71.9%) n= 164 (45.7%) n= 420 (62.6%)
OS overall survival
Table 3. Final model for overall survival in the development cohort
(no covariates were removed from the full model)
HR 2.5% 97.5% P
Age 1.03 1.02 1.04 <0.01
Gender, Female (ref)
Male 1.19 0.96 1.47 0.12
HPV–/p16– (ref )
HPV–/p16+ 1.01 0.63 1.64 0.96
HPV+/p16– 0.75 0.51 1.10 0.14
HPV+/p16+ 0.39 0.26 0.58 <0.01
Smoking, Current (ref )
Former 0.62 0.49 0.77 <0.01
Never 0.54 0.38 0.77 <0.01
UICC8 I (ref )
UICC8 II 0.97 0.66 1.44 0.88
UICC8 III 1.46 0.92 2.31 0.11
UICC8 IV 1.27 0.63 2.56 0.51
T1 (ref)
T2 1.39 1.02 1.87 0.03
T3 1.89 1.34 2.67 <0.01
T4 2.72 1.79 4.14 <0.01
N0 (ref )
N1 1.08 0.81 1.43 0.59
N2 1.40 0.94 2.08 0.10
N3 1.98 1.29 3.04 <0.01
M0 (ref)
M1 2.28 1.28 4.08 0.01
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Fig. 2 Predictive nomogram for overall survival. The nomogram is used by totalling the points identiﬁed on the top scale for each
independent covariate. The total points scale is used to identify the probability of 1-, 3- and 5-year survival
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Fig. 3 Calibration for 1-year (top row), 3-year (middle row) and 5-year overall survival. DK Denmark (development cohort)
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was used to predict the probability of death due to any cause at 1,
3 and 5 years after diagnosis (Fig. 2).
Figure 3 shows the calibration plots for internal and external
validation at 1, 3 and 5 years. The calibration model showed that
the log cumulative baseline hazard was shifted by −0.51 (95% CI:
−0.75 to –0.26) in the Swedish cohort, −0.35 (95% CI: −0.64 to
−0.05) in the German cohort and −0.34 (95% CI: −0.62 to −0.07)
in the UK cohort. The parameter regressing the log cumulative
baseline hazard in the development cohort on the log cumulative
baseline hazard in the German cohort was 0.83 (95% CI: 0.72–0.93)
corresponding to a less-steep increase in the German cohort. For
the Swedish and the UK cohort, the corresponding numbers were
0.91 (95% CI: 0.78–1.05) and 1.00 (95% CI: 0.85–1.15), respectively.
Finally, the speciﬁcation of the linear predictor for all three cohorts
appeared correct with conﬁdence intervals all including unity.
Harrell’s C index for the OS nomogram was 0.787 (95% CI
0.753–0.817), 0.772 (95% CI 0.747–0.817) and 0.766 (95% CI
0.746–0.788) for 1, 3 and 5 years, respectively. Similarly, external
validation after 1, 3 and 5 years, gave C-indexes for the Swedish
cohort of 0.836 (95% CI 0.775–0.881), 0.793 (95% CI 0.749–0.833)
and 0.780 (95% CI 0.743–0.815); for the German cohort 0.712 (95%
CI 0.655–0.764), 0.722 (95% CI 0.683–0.759) and 0.707 (95% CI
0.671–0.741) and for the UK cohort 0.815 (95% CI 0.775–0.864),
0.797 (95% CI 0.755–0.832) and 0.791 (95% CI 0.751–0.822). Brier
plots for OS are presented in Suppl. Fig. S1 and histograms of the
linear predictor plots are shown in Suppl. Fig. S2.
Progression-free survival
In total, 540 (41%) patients in the development cohort experi-
enced disease progression or death, with 187 (24%) patients in the
HPV+/p16+ subgroup vs. 274 (66%) patients in the HPV–/p16–
subgroup (p < 0.001). Crude cumulative incidence of progression
or death in the development cohort was at 5 years, 28% (95% CI
25–32%) for the HPV+/p16+ patient group and 71% (95% CI
66–75%) for the HPV–/p16– patient group (Fig. 4). In the validation
cohorts, 208 (61%) of 344 patients in the German, 162 (32%) of
503 in the Swedish and 158 (34%) of 463 in the UK cohort
developed disease progression or death. Follow-up times are
given in Suppl. Table S1. In the multivariable model, the AIC
backward- selection procedure led to exclusion of the variable
UICC-8 staging and inclusion of the covariates age, gender,
combined HPV and p16 status, smoking, T-, N- and M-classiﬁcation
(Table 4).
The nomogram for prediction of PFS at 1, 3 and 5 years is
shown in Fig. 5. Harrell’s C index of the development cohort was
0.733 (95% CI 0.703–0.760), 0.728 (95% CI 0.704–0.750) and 0.725
(95% CI 0.703–0.747) at 1, 3 and 5 years. External validation of the
nomogram for PFS after 1, 3 and 5 years, gave C-indexes of 0.805
(95% CI 0.745–0.852), 0.763 (95% CI 0.722–0.802) and 0.764 (95%
CI 0.724–0.801), respectively, for the Swedish cohort; 0.714 (95% CI
0.663–0.761), 0.711 (95% CI 0.671–0.748) and 0.704 (95% CI
0.667–0.738), respectively, for the German cohort and 0.797 (95%
CI 0.739–0.842), 0.778 (95% CI 0.735–0.812) and 0.771 (95% CI
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Fig. 4 Kaplan–Meier curves depicting progression-free survival probability for HPV+/p16+ patients vs. HPV–/p16– patients
Development and external validation of nomograms
C Grønhøj et al.
1677
0.731–0.805), respectively, for the UK cohort. The parameter
regressing the log cumulative baseline hazard in the development
cohort on the log cumulative baseline hazard in the German
cohort was 0.88 (95% CI: 0.69–1.07), in the Swedish cohort 1.16
(95% CI: 0.97–1.36) and in the UK cohort 1.20 (95% CI: 0.99–1.40).
The speciﬁcation of the model for all cohorts appeared correct
with conﬁdence intervals all including unity. Calibration plots for
internal and external validation of PFS are shown in Fig. 6, Brier
plots in Suppl. Fig. S3 and histograms of the linear predictor plots
in Suppl. Fig. S4.
DISCUSSION
This study presents multinational-validated nomograms for OS
and PFS for patients with OPSCC. One of the main ﬁndings
includes the identiﬁcation of combined HPV-DNA and p16 status
as an important and independent predictor for OS and PFS. The
nomograms performed well in external validation across areas
with high and low HPV prevalence. These models may facilitate
discussions in clinical settings and aid in identifying lower-risk
patients who could be candidates for de-escalation therapy, as
well as higher-risk patients eligible for treatment-escalation trials.
The online nomogram (www.orograms.org) can be used for more
precise calculations than drawing lines on the nomogram.
The signiﬁcance of the double biomarker can be exempliﬁed in
a typical patient case of a male, 60 years of age, nonsmoker, and
classiﬁed as T2N2M0, UICC-8 stage II. If the tumour is HPV+/p16+,
the 3- and 5-year OS estimates are 90% and 84%, respectively.
However, if the tumour is HPV–/p16+, the 3- and 5-year OS
estimates fall to 72% and 60%, respectively. Similar reductions are
seen in PFS estimates when comparing HPV+/p16+ with HPV–/
p16+ tumours. Although these numbers are estimates, they
underline the importance of evaluating patient prognosis using
the combined biomarker of HPV and p16.
Notably, HPV+/p16+ patients with T1–T2 and N1 tumours
could be considered candidates for de-escalation therapy, as their
survival is similar to the background population,34 and this might
avoid some of the morbidity associated with therapy. Our models
Table 4. Final model for progression-free survival in the development
cohort (UICC-8 staging was removed from the full model)
HR 2.5% 97.5% P
Age 1.01 1.01 1.02 <0.01
Gender, Female (ref )
Male 1.24 1.02 1.51 0.03
HPV–/p16– (ref )
HPV–/p16+ 0.91 0.65 1.26 0.57
HPV+/p16– 0.75 0.52 1.09 0.13
HPV+/p16+ 0.41 0.33 0.52 <0.01
Smoking, Current (ref )
Former 0.64 0.52 0.78 <0.01
Never 0.63 0.47 0.85 <0.01
T1 (ref)
T2 1.43 1.09 1.87 0.01
T3 1.81 1.36 2.41 <0.01
T4 3.10 2.27 4.25 <0.01
N0 (ref )
N1 1.17 0.92 1.50 0.20
N2 1.61 1.24 2.09 <0.01
N3 2.02 1.53 2.66 <0.01
M0 (ref)
M1 1.79 1.02 3.13 0.04
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Fig. 5 Predictive nomogram for progression-free survival. The nomogram is used by totalling the points identiﬁed on the top scale for each
independent covariate. The total points scale is used to identify the probability of 1-, 3- and 5-year survival
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also encourage studies to better understand whether HPV+/p16+
patients with N2 and N3 tumours are eligible for de-escalation as
well. Notably, at least nine de-escalation treatment trials are
ongoing or ﬁnishing.35 Our nomograms are likely to be applicable
to these and future trials, as we report similar 5-year survival
or progression rates as in North America,36–38 Western,39–41
Southern,42 and Northern Europe,2,43 Australia44 and China.45
One of the strengths in this study is the joint use of HPV and
p16 for scoring tumours. Other advantages are the large sizes of
the development and validation cohorts, all from areas with
universal, tax-ﬁnanced health-care systems diminishing selection
bias. In a previous smaller study in a region with very low HPV
prevalence (<20%), the development cohort was not from a
population-based, non-selected setting when constructing nomo-
grams for OS and PFS in OPSCC patients.17 A recently published
nomogram from the United States, also with smaller cohorts,
mainly included patients from private hospitals, and did not
include the important double biomarker of HPV and p16.18 This
study also had difﬁculties in showing the signiﬁcance of p16 alone
for, e.g. PFS.
In this study, we chose overall survival instead of disease-
speciﬁc survival as a primary endpoint because it represents the
cumulative effect of competing diseases, treatment morbidity and
age on patient survival. As disease progression is associated with
signiﬁcantly poorer outcome and consequently a decrease in
quality of life, we developed a nomogram with PFS as the
endpoint. The PFS nomogram therefore complements the overall
survival nomogram well.
Although our training cohort is population based and selection
bias is minimised, the nomograms have limitations. With respect
to accuracy, the CIs at the various predicted probabilities of
recurrence should be considered if using these nomograms in
clinical settings. The ﬁnal models performed well in calibration
and discrimination, but the level (risk of outcomes) is––as
expected––not identical across cohorts. This is most evident in
the German cohort, and this risk should be taken into account
when using the models. The German cohort might perform worse
due to several factors; partly a signiﬁcantly lower HPV prevalence,
higher smoking, higher share of patients who experience
progression and a greater share of patients in advanced stage
(e.g. stage 3 and 4). Although this is adjusted for, it should be
considered whether these nomograms are best suitable in HPV-
high-risk areas. A possible other bias in this model is the number
of censored patients, as observed in the crude-survival analysis.
The Danish, UK and Swedish centres have ~60–70% censorship
opposed to the German with merely 45% censored patients.
These nomograms are only applicable for patients who
underwent evaluation at multidisciplinary head and neck cancer
centres, as performance of the nomograms is likely to be worse for
patients who do not attend multidisciplinary evaluation.
p16 overexpression is a standard surrogate biomarker for high-
risk HPV-associated OPSCC.23,46,47 But notably, p16 overexpression
is also present in a number of non-HPV-driven tumours probably
related to RAS and BRAF mutations48 although not in KRAS.49
Other head and neck carcinomas have proven to be HPV–/p16+
likely related to misconﬁgurations in the p16–Rb–cyclin-D1
pathway inducing cell cycle activation in HPV-negative
carcinomas.50
The prevalence of HPV-associated OPSCC ultimately depends
on the sensitivity and speciﬁcity detection method employed,
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and using different methods between cohorts as in this study,
might lead to discordant results in HPV/p16 testing. All four
centres employed different p16 and HPV-testing tools, which is
a potential shortcoming. All methods cover the most relevant
HR-HPV types (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59
and 66). However, the Ventana in situ method (UK cohort) is
highly sensitive but less speciﬁc opposed to ampliﬁcation of
HPV DNA by general primers (GP5+/6+) with presumed high
sensitivity and speciﬁcity (Danish, Swedish and German cohort),
and the subsequent detection of the PCR products with type-
speciﬁc probes, e.g. bead-based multiplex, might differ. A
limitation of this study is also the use of different p16
antibodies across centres, potentially leading to a discrepancy
in p16 positivity. Notably, more than 90% of all tumours in this
study are examined with the use of the same antibody (clone
E6H4). Preferably, a subset of tumours should be tested with all
methods to uncover potential shortcomings.
In conclusion, we developed and validated nomograms for
OPSCC patients and known HPV-DNA and p16 status. The
nomograms are applicable for both high and low HPV areas.
Combining HPV-DNA and p16 status is essential for accurate
prognostication. Future work might focus on validating our results
and incorporating additional prognostic factors, including nomo-
grams speciﬁc for salvage treatment for relapsed disease, as well
as including outcome measures which have shown to inﬂuence
outcome (i.e. weight loss, education and anaemia) and outcomes
such as histopathological evaluations.
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